Ipamorelin
These sentences are taken from FDA’s compounding-risk page and, where noted, the July 2026 advisory-committee agenda. They are not a finding that a substance works.
What the opened sources say
Section titled “What the opened sources say”- FDA’s Category 2 table lists ipamorelin acetate under 503B, added 29 September 2023. The safety text cites immunogenicity from aggregation or peptide-related impurities, unnatural amino acids, and a published study of serious adverse events including death when ipamorelin was given intravenously for gastric motility.
- The same page’s withdrawn table also lists ipamorelin acetate and says it remains in the Category 2 table because it is in Category 2 under the 503B interim policy. This page does not resolve that into a broader legal conclusion.
- FDA says it has not identified safety information for certain other injectable routes and therefore cannot tell whether the drug would cause harm by those routes.
Not stated here
Section titled “Not stated here”Legal effect beyond the words on those pages is not interpreted. No animal or human study is summarized, because none was opened.
This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.
See also
Section titled “See also”Page record
Sources
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (primary, accessed 2026-11-20)
- July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (primary, accessed 2026-11-20)
Referenced by
- BPC-157
- CJC-1295
- FDA Category 2 and withdrawn nominations
- GHK-Cu
- Melanotan II
- MOTS-c
- PCAC meeting, 23–24 July 2026
- Peptides
- TB-500
A link from another wiki page is not evidence. Facts should point at the sources above.